Sinil Pharmaceutical Co. Ltd (012790) — Cash Flow Quality Index
Sinil Pharmaceutical Co. Ltd (012790) has a Cash Flow Quality Index of 1.01x as of September 2025. Operating cash flow of ₩2.62 Billion exceeds net income of ₩2.61 Billion, indicating high earnings quality where cash backs reported profits. Explore 012790 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Sinil Pharmaceutical Co. Ltd Cash Flow Quality Index (2014–2024)
Historical Cash Flow Quality Index for Sinil Pharmaceutical Co. Ltd across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 012790 cash generation efficiency.
Annual Cash Flow Quality Index for Sinil Pharmaceutical Co. Ltd (2014–2024)
Year-by-year earnings quality comparison for Sinil Pharmaceutical Co. Ltd.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.59x | ₩22.69 Billion | ₩14.30 Billion | ▲ +42.8% |
| 2023 | 1.11x | ₩15.15 Billion | ₩13.64 Billion | ▼ -1.3% |
| 2022 | 1.13x | ₩13.69 Billion | ₩12.16 Billion | ▼ -32.6% |
| 2021 | 1.67x | ₩11.16 Billion | ₩6.68 Billion | ▲ +14.0% |
| 2020 | 1.47x | ₩11.06 Billion | ₩7.54 Billion | ▼ -13.5% |
| 2019 | 1.70x | ₩12.31 Billion | ₩7.26 Billion | ▲ +5.4% |
| 2018 | 1.61x | ₩9.19 Billion | ₩5.71 Billion | ▲ +52.1% |
| 2017 | 1.06x | ₩8.67 Billion | ₩8.20 Billion | ▼ -12.2% |
| 2016 | 1.20x | ₩12.09 Billion | ₩10.04 Billion | ▲ +10.4% |
| 2015 | 1.09x | ₩9.56 Billion | ₩8.76 Billion | ▲ +19.1% |
| 2014 | 0.92x | ₩9.33 Billion | ₩10.18 Billion | — |